Shares of specialty pharmaceutical company RVL Pharmaceuticals (NASDAQ:RVLP) are on the rise today on a disclosure that with the blessings of its Board, RVLP has been evaluating certain strategic alternatives.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
This includes talks on a potential acquisition of a specific counterparty in an all-stock deal as well as funding discussions for the combined entity.
At present, RVLP is focused on the commercialization of Upneeq for the treatment of acquired blepharoptosis and a strategic deal could lead to a diversified aesthetics company.
Overall, the Street has a $3 consensus price target on RVLP alongside a Moderate Buy consensus rating. Today’s price gains come after a nearly 52.1% drop in RVLP shares over the past six months.
Read full Disclosure
